Loading...
Takara Bio Inc.
TKBIF•PNK
Healthcare
Biotechnology
$23.20
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $8.49B in Q1 2024 to $15.76B in Q4 2024. Gross profit remained healthy with margins at 62% in Q4 2024 compared to 51% in Q1 2024. Operating income hit $3.74B last quarter, sustaining a consistent 24% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $4.49B. Net income rose to $2.42B, while earnings per share reached $20.09. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan